Change Agents Corporation (CHGA)
| Market Cap | 2.64M -37.1% |
| Revenue (ttm) | n/a |
| Net Income | -20.26M |
| EPS | -4.02 |
| Shares Out | 12.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 411,397 |
| Open | 0.2232 |
| Previous Close | 0.2197 |
| Day's Range | 0.2152 - 0.2299 |
| 52-Week Range | 0.1768 - 2.8990 |
| Beta | -0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About CHGA
Change Agents Corporation, together with its subsidiaries, develops innovative artificial intelligence platforms in the United States and China. It operates through Consumer Health Technology and Artificial Intelligence Content Technology Segment. The company offers automated video generation, enterprise documentation, and workflow automation solutions, as well as cellular therapy and generative AI publishing and software. It also distributes the KetoAir device, which is a breathalyzer system that detects acetone levels in exhaled breath; and t... [Read more]
Financial Performance
Financial StatementsNews
Change Agents Proxy statement: Proxy filing
Change Agents filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
Change Agents Registration statement: Registration filing
Change Agents filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Change Agents Expands into Counter Drone Technologies with the Launch of Autonomous Air Defense LLC and Appointment of Major General Malcolm Frost to the Advisory Board
FREEHOLD, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Change Agents Corp. ("Change Agents" or the "Company") (Nasdaq: CHGA), a developer of agentic artificial intelligence (“AI”) software solutions, today...
Avalon GloboCare Announces Strategic Transformation into Agentic AI Software Company; Rebrands as Change Agents Corp.
Company to begin trading tomorrow under new Nasdaq ticker symbol CHGA as it advances its portfolio of agentic AI software platforms, including Beacon and Catch-Up
Avalon GloboCare Expands AI Product Portfolio with Planned Launch of Beacon, an Agentic Generative Engine Optimization Platform for Small Businesses
FREEHOLD, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a technology innovation company developing products for high-growth health and tech...
Chief Patrick Flannelly Highlights KetoAir™ Progress in Supporting the Nevada First Responders Holistic Health Reset Program
FREEHOLD, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a technology-innovation company with a strategic focus on developing innovative pro...
Avalon GloboCare Appoints Seasoned AI and Finance Executive as Chief Financial Officer
FREEHOLD, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a technology-innovation company with a strategic focus on developing innovative pro...
Avalon Quantum AI teams up with Caylent and Amazon Web Services on Agentic AI Platform Development
AWS collaboration accelerates Catch-Up Phase 2 development to a fully autonomous Agentic AI Video Platform AWS collaboration accelerates Catch-Up Phase 2 development to a fully autonomous Agentic AI V...
Avalon GloboCare Announces Closing of up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules
$3.25 Million Upfront With up to Approximately $6.5 Million of Potential Aggregate Proceeds Upon the Exercise in Full of Warrants $3.25 Million Upfront With up to Approximately $6.5 Million of Potenti...
Avalon GloboCare Announces up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules
$3.25 Million Upfront With up to Approximately $6.5 Million of Potential Aggregate Proceeds Upon the Exercise in Full of Warrants $3.25 Million Upfront With up to Approximately $6.5 Million of Potenti...
Avalon GloboCare Regains Compliance with Nasdaq Stockholders' Equity Requirement, Launches Marketing for Automated Generative AI Video Platform
FREEHOLD, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer p...
Avalon GloboCare Board Director Highlights RPM Interactive's Automated Generative AI Video Creation Platform in Interview with ProactiveInvestors.com
FREEHOLD, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that Michael...
E.F. Hutton Advises on RPM Interactive's Acquisition by Avalon GloboCare
NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- E.F. Hutton & Co., a leading investment bank providing strategic advisory and capital markets services, today is proud to have served as exclusive financial...
Myseum Completes Sale of Minority Stake in RPM Interactive for Approximately $6.5 Million in Avalon GloboCare Acquisition
NEW BRUNSWICK, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Myseum, Inc. (Nasdaq: MYSE) (“Myseum” or the “Company”) today announced the completion of the sale of its approximately 34% ownership interest in...
Avalon GloboCare Acquires RPM Interactive, a Generative AI Software Company, in an All-Stock Transaction
Company forms a new subsidiary, Avalon Quantum AI, LLC, in connection with the acquisition Acquisition expected to resolve Nasdaq minimum stockholders' equity deficiency RPM Interactive has developed ...
Avalon GloboCare Reports Q3 2025 Progress with KetoAir™, Holistic Health Initiatives, and International Expansion
FREEHOLD, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced a series of ...
Avalon GloboCare to Launch Online Sales of KetoAir Breathalyzer in the United Kingdom
FREEHOLD, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it will...
Avalon GloboCare Enters into Distribution Agreement with Saga Health for KetoAir Targeting First Responders
FREEHOLD, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that its sub...
Avalon GloboCare Announces Patent Issuance for Novel CAR-T and CAR-NK Cell Technology in Hong Kong
FREEHOLD, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance...
Avalon GloboCare and Qi Diagnostics Enter into Definitive Agreement to Co-Develop Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
FREEHOLD, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it ente...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN and ALBT on Behalf of Shareholders
NEW YORK , March 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...
Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today anno...
Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today anno...
Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Colle...
Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diag...